Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Cell

• Publication date

  2013-07-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ccr.2013.06.002PMID 23845444
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Snapshot of Breast Cancer

  2014cited by this paper
• Patient-derived breast tumor xenografts facilitating personalized cancer therapy

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013influential reference
• ABT-199: Taking Dead Aim at BCL-2

  2013cited by this paper
• Targeting BCL-2 in breast cancer: exploiting a tumor lifeline to deliver a mortal blow?

  2013cited by this paper
• ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.

  2013influential reference
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Apoptosis therapy: driving cancers down the road to ruin

  2013cited by this paper
• ABT-199: taking dead aim at BCL-2.

  2013cited by this paper
• Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.

  2012influential reference
• Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

  2012cited by this paper
• Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

  2012influential reference
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• SnapShot: breast cancer.

  2012cited by this paper
• A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER‐positive breast cancer

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Targeting the B-cell lymphoma/leukemia 2 family in cancer.

  2012cited by this paper
• The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

  2011cited by this paper
• Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737

  2011influential reference
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

  2011cited by this paper
• Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

  2011cited by this paper
• Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

  2011cited by this paper
• A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

  2011cited by this paper
• Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases

  2011cited by this paper
• Aberrant Expression of Apoptosis-Related Molecules in Endometriosis

  2011cited by this paper
• American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

  2010cited by this paper
• BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

  2010cited by this paper
• BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

  2010cited by this paper
• American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

  2010cited by this paper
• Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer

  2010cited by this paper
• Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERα

  2009cited by this paper
• ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

  2008cited by this paper
• Programmed anuclear cell death delimits platelet life span.

  2007cited by this paper
• Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

  2007cited by this paper
• Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

  2006cited by this paper
• Current development of mTOR inhibitors as anticancer agents

  2006cited by this paper
• Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

  2006cited by this paper
• mTOR-dependent Suppression of Protein Phosphatase 2A Is Critical for Phospholipase D Survival Signals in Human Breast Cancer Cells*

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• The Bcl-2 family: roles in cell survival and oncogenesis

  2003cited by this paper
• Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

  2002cited by this paper
• Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.

  2001cited by this paper
• Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α

  2001cited by this paper
• Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

  1997cited by this paper
• The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone.

  1995influential reference

• ABT-737 efficiently inhibits hepatocellular carcinoma cell activity via regulating PANoptosis.

  2026cites this paper
• A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis

  2025cites this paper
• Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes

  2025cites this paper
• Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer.

  2025cites this paper
• Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-263

  2025cites this paper
• Unraveling the underlying mechanisms of cancer stem cells in therapeutic resistance for optimizing treatment strategies

  2025cites this paper
• ALKBH1 drives tumorigenesis and drug resistance via tRNA decoding reprogramming and codon-biased translation.

  2025cites this paper
• Discovery of a novel BCL-2 inhibitor GW806742X for the treatment of TNBC.

  2025cites this paper
• Identification of Therapeutic Gene Targets in Triple-Negative Breast Cancer: A Hybrid Approach Integrating Semidefinite Programming, Boolean Simulation, and Druggability Analysis

  2025cites this paper
• Zebrafish Avatar testing preclinical study predicts chemotherapy response in breast cancer

  2025cites this paper
• A comprehensive luminal breast cancer patient‐derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors

  2024cites this paper
• Targeting Bcl-2 with Indole Scaffolds: Emerging Drug Design Strategies for Cancer Treatment.

  2024cites this paper
• Combination of fruquintinib with venetoclax for the treatment of colorectal cancer

  2024cites this paper
• Newer combination treatments for breast cancer coexisting with acute myeloid leukemia in the novel regimens era: A case report and literature review

  2024cites this paper
• Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review

  2024cites this paper
• Cell Death: Mechanisms and Potential Targets in Breast Cancer Therapy

  2024cites this paper
• Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family.

  2024cites this paper
• ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia

  2023cites this paper
• Innovative Thiosemicarbazones that Induce Multi-Modal Mechanisms to Down-Regulate Estrogen-, Progesterone-, Androgen- and Prolactin-Receptors in Breast Cancer.

  2023cites this paper
• Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.

  2023cites this paper
• Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers

  2023cites this paper
• An Innovative Non-Hormonal Strategy Targeting Redox Active Metals to Down-Regulate Estrogen-, Progesterone-, Androgen- and Prolactin-Receptors in Breast Cancer

  2023cites this paper
• Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma

  2023cites this paper
• Small molecule inhibition of TFF3 overcomes tamoxifen resistance and enhances taxane efficacy in ER+ mammary carcinoma.

  2023cites this paper
• Simultaneous Inhibition of Mcl-1 and Bcl-2 Induces Synergistic Cell Death in Hepatocellular Carcinoma

  2023cites this paper
• Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

  2023cites this paper
• Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family.

  2023cites this paper
• Anticancer and anti-metastasis activity of 1,25 dihydroxycholecalciferols and genistein in MCF-7 and MDA-MB-231 breast cancer cell lines

  2023cites this paper
• Involvement of necroptosis in the selective toxicity of the natural compound (±) gossypol on squamous skin cancer cells in vitro

  2023cites this paper
• Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer

  2023cites this paper
• Pharmacological Targeting of Bcl-2 Induces Caspase 3-Mediated Cleavage of HDAC6 and Regulates the Autophagy Process in Colorectal Cancer

  2023cites this paper
• Activable Targeted Protein Degradation Platform Based on Light-triggered Singlet Oxygen.

  2022cites this paper
• Therapeutics targeting BCL2 family proteins

  2022cites this paper
• Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy.

  2022cites this paper
• Bcl-xL Inhibition Radiosensitizes PIK3CA/PTEN Wild-type Triple-negative Breast Cancers with Low Mcl-1 Expression

  2022cites this paper
• MCL-1 is a clinically targetable vulnerability in breast cancer

  2022cites this paper
• Co-encapsulation of PI3-Kδ/HDAC6 dual inhibitor and Navitoclax in Quatramer™ nanoparticles for synergistic effect in ER+ breast cancer.

  2022cites this paper
• Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling

  2022cites this paper
• Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models

  2022cites this paper
• Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer

  2022cites this paper
• Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction

  2022cites this paper
• Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer

  2022cites this paper
• Antitumor Effect of Demethylzeylasteral (T-96) on Triple-Negative Breast Cancer via LSD1-Mediate Epigenetic Mechanisms

  2022cites this paper
• Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics

  2022cites this paper
• Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy

  2022cites this paper
• Sensitization effect of kaempferol from persimmon leaves on HepG2 hepatoma cells with ABT-199 resistance and its molecular mechanisms

  2022cites this paper
• PALVEN: phase 1b trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer.

  2022cites this paper
• Endogenous and imposed determinants of apoptotic vulnerabilities in cancer.

  2022cites this paper
• VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

  2022cites this paper
• BH3-mimetics: recent developments in cancer therapy

  2021cites this paper
• Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors

  2021influential citation
• Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells

  2021cites this paper
• Cell-penetrating Alphabody protein scaffolds for intracellular drug targeting

  2021cites this paper
• Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges

  2021cites this paper
• B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy

  2021influential citation
• Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy

  2021cites this paper
• New targets in endocrine-resistant hormone receptor-positive breast cancer.

  2021cites this paper
• The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

  2021cites this paper
• Potential applications of BPFP1 in Bcl-2 protein quantification, carcinoma cell visualization, cell sorting and early cancer diagnosis.

  2021cites this paper
• Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas

  2021cites this paper
• Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers

  2021cites this paper
• CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors

  2021cites this paper
• Identification of Dipeptidyl Peptidase (DPP) Family Genes in Clinical Breast Cancer Patients via an Integrated Bioinformatics Approach

  2021cites this paper
• The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia

  2021cites this paper
• Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target.

  2021cites this paper
• Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer

  2021cites this paper
• The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy.

  2021cites this paper
• The Multifaceted Functions of Autophagy in Breast Cancer Development and Treatment

  2021cites this paper
• The anti‐apoptotic Bcl‐2 protein regulates hair follicle stem cell function

  2021cites this paper
• ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins

  2021influential citation
• Therapeutic Silencing of BCL-2 Using NK Cell-Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer

  2021cites this paper
• The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents

  2021influential citation
• MicroRNA-1: Diverse role of a small player in multiple cancers.

  2021cites this paper
• Targeting Bcl-2 for cancer therapy.

  2021cites this paper
• A precision approach to breast cancer treatment based on cell lineage-specific vulnerabilities

  2021cites this paper
• BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer

  2021cites this paper
• Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.

  2021cites this paper
• Patient-Derived Xenograft Models in Breast Cancer Research.

  2021cites this paper
• Understanding and drugging the Bcl-2 transmembrane interactome for tumor treatment

  2020cites this paper
• The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors

  2020cites this paper
• Estrogen receptor positive breast cancer patient–derived xenograft models in translational research

  2020cites this paper
• Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent

  2020cites this paper
• Targeting of BCL-2 Family Members during Anticancer Treatment: A Necessary Compromise between Individual Cell and Ecosystemic Responses?

  2020cites this paper
• Targeting triple-negative breast cancers with the Smac-mimetic birinapant

  2020cites this paper
• Efficacy and molecular mechanisms of the BH3-mimetic venetoclax (ABT-199) in pediatric acute lymphoblastic leukemia

  2020cites this paper
• Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer.

  2020cites this paper
• Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer

  2020influential citation
• Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer

  2020cites this paper
• Low DEDD expression in breast cancer cells indicates higher sensitivity to the Bcl-2-specific inhibitor ABT-199.

  2020cites this paper
• Hydrogen Sulfide Attenuates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Inhibiting Apoptosis and Promoting Autophagy via Reactive Oxygen Species/Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Signaling Pathway

  2020cites this paper
• Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer

  2020cites this paper
• Hormone Effects on Tumors

  2020cites this paper
• CHK2 inhibition provides a strategy to suppress hematological toxicity from PARP inhibitors

  2020cites this paper
• Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

  2020cites this paper
• CMAR_A_249041 3547..3560

  2020cites this paper
• BCL(X)L and BCL2 increase the metabolic fitness of breast cancer cells: a single-cell imaging study

  2020cites this paper
• Bifurcation Analysis of a Mathematical Model of Tumor Growth in MCF-7 Breast Cancer Cell Line

  2020cites this paper
• Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells

  2020cites this paper
• Systemic treatment of metastatic breast cancer: SABCS 2018

  2019cites this paper
• Wenetoklaks w leczeniu chorób układu krwiotwórczego i guzów litych

  2019cites this paper